Jazz Pharmaceuticals (JAZZ) EVP exercises options and sells 6,907 shares

Rhea-AI Filing Summary

Jazz Pharmaceuticals executive Samantha Pearce reported an exercise-and-sale transaction in company stock. On May 28, 2026, the EVP, Chief Commercial Officer exercised non-qualified stock options to acquire 6,907 ordinary shares at an exercise price of $109.45 per share and sold 6,907 ordinary shares in an open-market transaction at $235.41 per share. Following these transactions, she directly owns 50,272 ordinary shares. The exercised options were granted under the company’s 2011 Equity Incentive Plan and had fully vested by March 2, 2024, and this specific option grant is now fully exercised.

Insider Trade Summary

Net Seller: 6,907 shares ($1,625,977)

Net Sell 3 txns

Insider Pearce Samantha

Role EVP, Chief Commercial Officer

Sold 6,907 shs ($1.63M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	6,907	$0.00	--
Exercise	Ordinary Shares	6,907	$109.45	$756K
Sale	Ordinary Shares	6,907	$235.41	$1.63M

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 shares (Direct, null); Ordinary Shares — 57,179 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 6,907 shares Sale price per share: $235.41 per share Shares acquired via exercise: 6,907 shares +3 more

6 metrics

Shares sold 6,907 shares Open-market sale of ordinary shares on May 28, 2026

Sale price per share $235.41 per share Price for 6,907 ordinary shares sold May 28, 2026

Shares acquired via exercise 6,907 shares Ordinary shares from non-qualified stock option exercise

Option exercise price $109.45 per share Non-qualified stock option exercise price for 6,907 shares

Shares owned after transaction 50,272 shares Direct ownership of ordinary shares after May 28, 2026

Option expiration date May 6, 2030 Expiration for the non-qualified stock option grant exercised

Key Terms

Non-Qualified Stock Option, open-market sale, 2011 Equity Incentive Plan, vested, +1 more

5 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

2011 Equity Incentive Plan financial

"These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan."

vested financial

"The option was fully vested as of March 2, 2024."

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pearce Samantha

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/28/2026		M		6,907	A	$109.45	57,179	D
Ordinary Shares	05/28/2026		S		6,907	D	$235.41	50,272	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$109.45	05/28/2026		M			6,907	(1)	05/06/2030	Ordinary Shares	6,907	$0.0	0	D

Explanation of Responses:

1. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vested in 36 equal monthly installments thereafter. The option was fully vested as of March 2, 2024.

	By: /s/Paz Dizon, as attorney in fact For: Samantha J. Pearce	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) executive Samantha Pearce report?

Samantha Pearce reported an exercise-and-sale transaction involving 6,907 Jazz Pharmaceuticals ordinary shares. She exercised non-qualified stock options at $109.45 per share and sold 6,907 shares at $235.41 per share in an open-market transaction on May 28, 2026.

How many Jazz Pharmaceuticals shares did Samantha Pearce sell in this Form 4 filing?

Samantha Pearce sold 6,907 Jazz Pharmaceuticals ordinary shares in an open-market transaction. The reported sale price was $235.41 per share, and it occurred on May 28, 2026, as part of a transaction linked to an option exercise on the same date.

At what price did Samantha Pearce exercise her Jazz Pharmaceuticals stock options?

She exercised non-qualified stock options at an exercise price of $109.45 per Jazz Pharmaceuticals ordinary share. These options covered 6,907 shares, were granted under the 2011 Equity Incentive Plan, and were fully vested as of March 2, 2024 before the reported exercise.

How many Jazz Pharmaceuticals shares does Samantha Pearce own after the reported transactions?

After the reported transactions, Samantha Pearce directly owns 50,272 Jazz Pharmaceuticals ordinary shares. This post-transaction holding reflects her position following the exercise of 6,907 options and the same-day open-market sale of 6,907 ordinary shares on May 28, 2026.

What happened to the specific stock option grant disclosed in Samantha Pearce’s Jazz Pharmaceuticals Form 4?

The non-qualified stock option grant for 6,907 shares was fully exercised, leaving zero options remaining from that grant. It had an exercise price of $109.45 per share, was granted under the 2011 Equity Incentive Plan, and was fully vested by March 2, 2024.

Under which plan were Samantha Pearce’s exercised Jazz Pharmaceuticals options granted?

The exercised options were granted under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan. They covered 6,907 ordinary shares, vested over four years from a March 2, 2020 vesting commencement date, and were fully vested as of March 2, 2024 before the exercise.